We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$5.05B
1-Year Est. Return
125.28%
This Fund
S&P 500
This Quarter
Est. Return
+39.82%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$11.4B
AUM Growth
+$3.47B
(+44%)
Cap. Flow
+$1.27B
Cap. Flow
% of AUM
11.12%
Top 10 Holdings %
Top 10 Hldgs %
37.58%
Holding
169
New
25
Increased
27
Reduced
20
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbCellera Biologics
ABCL
|
+$384M |
| 2 |
ARS Pharmaceuticals
SPRY
|
+$292M |
| 3 |
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
|
+$154M |
| 4 |
Pfizer
PFE
|
+$133M |
| 5 |
UnitedHealth
UNH
|
+$131M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$259M |
| 2 |
XLRN
Acceleron Pharma
XLRN
|
+$67.6M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$65.8M |
| 4 |
Exelixis
EXEL
|
+$58.8M |
| 5 |
Biogen
BIIB
|
+$48.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.2% |
| 2 | Financials | 0.52% |
| 3 | Technology | 0.5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MRSN
101
DELISTED
Mersana Therapeutics
MRSN
| $20.6M | 0.18% |
30,934
-22,220
| -42% | -$12.4M |
|
|
KDNY
102
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $19.8M | 0.17% |
+1,250,001
| New | +$18.9M |
|
103
Larimar Therapeutics
LRMR
$390M
| $19M | 0.17% |
886,560
| – | – |
|
104
Teva Pharmaceuticals
TEVA
$40.1B
| $18.7M | 0.16% |
1,935,200
| – | – |
|
105
Verrica Pharmaceuticals
VRCA
$91.9M
| $17M | 0.15% |
147,973
| – | – |
|
|
SYRS
106
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $17M | 0.15% |
+156,250
| New | +$14.3M |
|
107
Vaxcyte
PCVX
$7.72B
| $16.7M | 0.15% |
630,260
-10,500
| -2% | -$390K |
|
108
Milestone Pharmaceuticals
MIST
$129M
| $16.7M | 0.15% |
2,493,109
+2,107,318
| +546% | +$14.1M |
|
|
CMPS
109
Compass Pathways
CMPS
$1.45B
| $16.7M | 0.15% |
350,000
| – | – |
|
|
IMGN
110
DELISTED
Immunogen Inc
IMGN
| $16.5M | 0.14% |
+2,553,900
| New | +$14.9M |
|
111
Zymeworks
ZYME
$1.63B
| $15M | 0.13% |
317,002
-24,100
| -7% | -$1.12M |
|
112
BiomX
PHGE
$1.95M
| $14.8M | 0.13% |
12,176
| – | – |
|
113
VistaGen Therapeutics
VTGN
$9.75M
| $14.6M | 0.13% |
+250,000
| New | +$6.38M |
|
114
Relay Therapeutics
RLAY
$3.99B
| $14.5M | 0.13% |
350,000
| – | – |
|
115
Acadia Pharmaceuticals
ACAD
$4.44B
| $14.2M | 0.12% |
265,772
+158,772
| +148% | +$7.88M |
|
116
Praxis Precision Medicines
PRAX
$8.26B
| $14.1M | 0.12% |
+17,040
| New | +$9.95M |
|
117
ALX Oncology
ALXO
$264M
| $12.9M | 0.11% |
+150,000
| New | +$9.02M |
|
|
BLU
118
DELISTED
BELLUS Health Inc.
BLU
| $12.6M | 0.11% |
4,189,593
-947,623
| -18% | -$2.57M |
|
119
Gilead Sciences
GILD
$166B
| $11.2M | 0.1% |
192,200
| – | – |
|
|
TECX
120
Tectonic Therapeutic
TECX
$553M
| $11.1M | 0.1% |
66,143
| – | – |
|
121
Protara Therapeutics
TARA
$221M
| $10.9M | 0.1% |
450,000
| – | – |
|
122
Viatris
VTRS
$20.9B
| $10M | 0.09% |
+535,149
| New | +$8.73M |
|
123
Nurix Therapeutics
NRIX
$2.45B
| $9.86M | 0.09% |
300,000
| – | – |
|
124
Pulmonx
LUNG
$52.8M
| $8.63M | 0.08% |
+125,000
| New | +$6.12M |
|
125
CALL
Sarepta Therapeutics
SRPT
$1.6B
| $8.53M | 0.07% |
+50,000
| New | +$7.41M |
|
Similar funds
HSA
LIM
NL
BPWM
LFG
JIM
CTC
PAMP
OrbiMed's Q4 2020 Portfolio in Review
As of Q4 2020, OrbiMed held 169 positions worth $11.4B, up 44% from $7.96B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
OrbiMed deployed $1.27B of net new capital in Q4 2020, opening 25 new positions and adding to 27 existing holdings. Its largest new stake was AbCellera Biologics: 8,400,768 shares worth $338M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Financials and Technology.
On the sell side, the largest reduction was Alexion Pharmaceuticals, an estimated $259M trimmed.
- OrbiMed's largest Q4 2020 buy was AbCellera Biologics: 8,400,768 shares worth $338M.
- OrbiMed added most to Xtant Medical Holdings in Q4 2020, an estimated $81.8M increase.
- OrbiMed's biggest Q4 2020 reduction was Alexion Pharmaceuticals, cutting an estimated $259M.
- OrbiMed fully exited Acceleron Pharma in Q4 2020, selling an estimated $67.6M.
- OrbiMed's ten largest holdings make up 38% of its $11.4B portfolio in Q4 2020.
- OrbiMed opened 25 new positions and closed 20 in Q4 2020.
- OrbiMed's portfolio value rose 44% quarter-over-quarter to $11.4B.
Based on OrbiMed's 13F filing for Q4 2020, filed 16 Feb 2021.